Secondary Progressive Multiple Sclerosis Clinical Trials | A Drug Pipeline Analysis Report 2024

DelveInsight's 'Secondary Progressive Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Secondary Progressive Multiple Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Secondary Progressive Multiple Sclerosis pipeline domain.
Download a sample report @ https://www.delveinsight.com/report-store/secondary-progressive-multiple-sclerosis-spms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Secondary Progressive Multiple Sclerosis Pipeline Report
Over 5+ Secondary Progressive Multiple Sclerosis pipeline therapies are in various stages of development, and their anticipated acceptance in the Secondary Progressive Multiple Sclerosis market would significantly increase market revenue.
Leading Secondary Progressive Multiple Sclerosis companies developing novel drug candidates to improve the Secondary Progressive Multiple Sclerosis treatment landscape include Sanofi, Medicinova, Immune Response Biopharma, AB Science, and others.
Promising Secondary Progressive Multiple Sclerosis pipeline therapies in various stages of development include Tolebrutinib, Ibudilast, NeuroVax, Masitinib, and others.
Secondary Progressive Multiple Sclerosis Overview
Secondary Progressive Multiple Sclerosis (SPMS) is a form of Multiple Sclerosis (MS) that follows an initial period of relapsing-remitting MS (RRMS). In SPMS, the disease progresses steadily over time, with or without occasional relapses and remissions. This progressive worsening of symptoms is due to the ongoing damage to the myelin sheath that insulates nerve fibers and the nerve fibers themselves in the central nervous system (CNS).

Key Features of Secondary Progressive Multiple Sclerosis:

1. Progression of Disability: SPMS is characterized by a gradual and steady worsening of neurological symptoms and disability. This progression can affect various functions, including mobility, cognitive abilities, vision, and bladder control.

2. Variable Onset: The transition from RRMS to SPMS can occur at different times for different individuals. Some people may experience a more rapid progression, while others may have a slower decline.

3. Relapses and Remissions: While the disease primarily progresses, some individuals with SPMS may still experience relapses (exacerbations) and remissions (periods of stability or slight improvement). However, these are less common and less pronounced than in the relapsing-remitting phase.

4. Pathology: The underlying pathology involves continued inflammation, demyelination, and neurodegeneration in the CNS. This leads to the accumulation of disability over time.

5. Diagnosis: Diagnosing SPMS can be challenging and typically involves a combination of clinical evaluation, MRI imaging, and a review of the patient's history of MS symptoms and disease course.

6. Treatment: There is no cure for SPMS, but treatment focuses on managing symptoms, slowing disease progression, and improving quality of life. Treatment options may include disease-modifying therapies, symptomatic treatments, and rehabilitation services.

7. Prognosis: The prognosis for individuals with SPMS varies widely. Some may experience a relatively slow progression of disability, while others may have a more rapid decline. Factors influencing the prognosis include the severity of the initial RRMS, the duration of the relapsing-remitting phase, and the effectiveness of treatment.

Management and Treatment:

- Disease-Modifying Therapies (DMTs): While not all DMTs are approved specifically for SPMS, some may help slow disease progression and reduce the frequency of relapses.

- Symptomatic Treatments: These address specific symptoms such as spasticity, pain, fatigue, and cognitive impairment. Examples include muscle relaxants, pain medications, and cognitive rehabilitation.

- Rehabilitation: Physical therapy, occupational therapy, and speech therapy can help manage disability and improve functional abilities.

- Lifestyle Modifications: Exercise, a healthy diet, and stress management techniques can also play a role in managing symptoms and improving overall well-being.

Secondary Progressive Multiple Sclerosis is a complex and challenging condition that requires a comprehensive and individualized approach to management. Ongoing research continues to explore new treatments and interventions to improve outcomes for individuals with SPMS.

To know more about in detail, visit: https://www.delveinsight.com/report-store/secondary-progressive-multiple-sclerosis-spms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Secondary Progressive Multiple Sclerosis Pipeline Analysis: Drug Profile
NeuroVax (Immune Response BioPharma) is a therapeutic TCR (T-cell receptor) peptide vaccine for SPMS. In March 2020, the company initiated a Phase II/III in patients with SPMS, currently the study is in recruiting phase. The study is estimated to complete by 2024, with an estimated enrollment of 200 participants. However, company has not provided any updates on the drug. In March 2014, NeuroVax was granted Fast Track Designation by FDA for SPMS.
Discover more about the emerging Secondary Progressive Multiple Sclerosis drugs @ https://www.delveinsight.com/sample-request/secondary-progressive-multiple-sclerosis-spms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Secondary Progressive Multiple Sclerosis Key Companies
Sanofi
Medicinova
Immune Response Biopharma
AB Science
Secondary Progressive Multiple Sclerosis Pipeline Therapies
Tolebrutinib
Ibudilast
NeuroVax
Masitinib
Secondary Progressive Multiple Sclerosis Pipeline Therapeutics Assessment
By development stage
By product type
By route of administration
By molecule type
By MOA type
Scope of the Secondary Progressive Multiple Sclerosis Pipeline Report
Coverage: Global
Key Secondary Progressive Multiple Sclerosis Companies: Sanofi, Medicinova, Immune Response Biopharma, AB Science, and others
Key Secondary Progressive Multiple Sclerosis Pipeline Therapies: Tolebrutinib, Ibudilast, NeuroVax, Masitinib, and others
Find out more about the Secondary Progressive Multiple Sclerosis treatment options in development @ https://www.delveinsight.com/sample-request/secondary-progressive-multiple-sclerosis-spms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.